# Targeted Anti-CEA CAR-T Immunotherapy for Advanced Lung Cancer

> **NCT06992583** · PHASE1 · RECRUITING · sponsor: **Chongqing Precision Biotech Co., Ltd** · enrollment: 60 (estimated)

## Conditions studied

- Advanced Lung Cancer

## Interventions

- **BIOLOGICAL:** Targeted CEA CAR-T
- **BIOLOGICAL:** Targeted CEA CAR-T

## Key facts

- **NCT ID:** NCT06992583
- **Lead sponsor:** Chongqing Precision Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-08
- **Primary completion:** 2028-02-29
- **Final completion:** 2028-04-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06992583

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06992583, "Targeted Anti-CEA CAR-T Immunotherapy for Advanced Lung Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06992583. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*